Advertisement / Advertisement
This news should send InnoCan Pharma* (NASDAQ: INN) stock skyrocketing again, perhaps even more violently than seen in recent days.
The insights that can be drawn from this news are too important to go unheeded.
The report, published shortly after the market closed on Friday, should attract the interest of many investors over the entire weekend, so that an explosive price development on Monday seems more than just likely.
BREAKING NEWS: INNOCAN PHARMA ANNOUNCES THINNOCAN PHARMA ANNOUNCES THE FILING BY RAMOT AT TEL AVIV UNIVERSITY OF AN INTERNATIONAL PATENT APPLICATION FOR ITS UNIQUE CANNABINOIDS LOADED EXOSOME DELIVERY PLATFORM (CLX)
InnoCan Pharma* (WKN: A2PSPW) announces that it has filed an international patent for its unique cannabinoid exosome (CLX) delivery platform.
The new patent application covers the capabilities and applications of a cannabinoid-loaded exosome and enables its precise delivery to target organs. This novel technique may enable better efficacy of drugs targeting different indications.Exosomes have shown promise as nanocarriers for drug delivery and targeted therapy. Exosomes can act as "guided missiles," targeting specific damaged organs and loaded with therapeutic ingredients to boost their potential.
The CLX (Cannabinoids Lauded Exosome) could have the potential to produce a highly synergistic effect of regenerative and anti-inflammatory properties targeting the recovery of infected lung cells and the central nervous system (CNS).
NEWS CONCLUSION:
Just a year ago, the idea of loading exosomes with CBD to combine the two well-known effects was nothing short of a bold plan. Today it becomes clear that the scientists around Prof. Dani Offen were able to put this into practice in order to finally be able to apply for a patent for this technology!
As also stated in the announcement, this technology is to be used in the treatment of infected lung cells, but also in diseases of the central nervous system (CNS). Logic alone dictates that this can work. When billions of nanometer-sized homing missiles, called exosomes, piggybacking on anti-inflammatory CBD molecules, swarm out to find damaged tissue so that the anti-inflammatory CBD can work right where it's needed, high therapeutic potency seems likely after all.
All kinds of lung infections, including COVID-19, but also all inflammatory diseases of the central nervous system such as meningitis, encephalitis or multiple sclerosis (!!! more about that in a moment !!!) could be on the future treatment list.
Most recently, InnoCan Pharma* (WKN: A2PSPW) was able to reveal important details about LPD technology - CBD molecules embedded in liposomes:
LATEST NEWS: INNOCAN PHARMA'S CBD-LOADED LIPOSOME PLATFORM TECHNOLOGY SHOWS EXTENDED RELEASE IN LARGE ANIMALS
The recent large animal LPD study (CBD encapsulated in liposomes administered by injection) showed a similar pharmacokinetic profile to a previous small animal study. This result should bring the company closer to clinical studies on humans. Pharmacokinetics (PK) determine the profile of drug concentrations in the blood as a function of time from the time of administration, thereby indicating the effectiveness of the drug. The "leap" from small animal model to large animal model is of immense importance in the development of the LPT platform for humans.
The data obtained suggest that InnoCan's LPT platform could be suitable for human therapeutic applications.
This allows for a one-time administration of CBD instead of daily administration and overcomes the low (10-20%) oral bioavailability of CBD. The superior pharmacokinetics of CBD in LPT may allow to achieve a controlled concentration of CBD in the blood, leading to a better clinical outcome.
ONLY ONE OF DOZENS OF POSSIBLE APPLICATIONS
CBD is proven to be anti-inflammatory. Many diseases are due to inflammation, but the bioavailability of CBD to the human body is low. Especially with multiple sclerosis, patients have had great success taking CBD. Both the LPD technology (CBD embedded in liposomes) and the CLX technology (CBD "piggyback" on exosomes) would almost impose themselves as treatment methods.
Be sure to read the following article and then answer the questions yourself: "Couldn't it be immensely beneficial to have consistently high levels of CBD in the body that can be achieved with the InnoCan Pharma* (NYSE:InnoCan Pharma*) LPD method of MS patients?Could a consistently high level of CBD in the body even stop MS?Could CBD, brought directly to the focus of inflammation with CLX technology, stop the chronic, ever-worsening nerve inflammation?
Source: Meduni.com
INNOCAN PHARMA CORP.*
WKN: A2PSPW CSE: INNO
Cool thing: With an account at Smartbroker you can trade this share from 0 euros. - Changing brokers often pays off!!
BLUECHIP POWER
The management and scientific advisory board of this company are of the highest caliber you would expect from a penny stock:
Example Prof. Barenholz: This is one of the most successful and probably also most famous scientists in Israel, Prof. Chezy Barenholz, who received the "Israeli Nobel Prize", the so-called EMET Prize, for his work in 2020.
The EMET Prize, known as "Israel's Nobel Prize," which is awarded for outstanding academic and professional achievements that have had far-reaching impact and made a significant contribution to Israeli society, announced its 2020 winners in five categories: culture and arts, Exact sciences, life sciences, social sciences and humanities.
The InnoCan Pharma* (NASDAQ: PHARM) crew, which could make even many blue-chip companies green with envy, has set the stage for some biotech innovations that could make it possible to solve pressing medical problems such as Covid-19, epilepsy or Alzheimer's easily treatable and maybe even curable.
The broader public is now also becoming aware of InnoCan Pharma (NYSE:INNOPHA) stock. Alex Newman names InnoCan in the same breath as Gilead Sciences (NASDAQ GILD) and CRIPR Therapeutics (NASDAQ: CRSP):
3 Biotech Stocks to Watch: investing.com
LPT: WITH INJECTABLE CBD AGAINST EPILEPSY:
Innocan achieves major milestone in developing its unique CBD-loaded liposome platform technology for injectable CBD.
InnoCan Pharma* (NASDAQ:RNP) announced that an animal study in mice showed prolonged release of cannabidiol ("CBD") into the blood for at least three weeks after administration. This study was conducted by the Hebrew University of Jerusalem, Israel.
The study, conducted by Dr. Ahuva Cern, senior researcher in the laboratory of Prof. Barenholz, was performed on over 35 mice in laboratories at the Hebrew University of Jerusalem. 21 days after injection, significant amounts of CBD were still found in the blood of mice treated with a single injection of liposomal CBD. In the second animal experiment it was even 50 days.
Cern, Bincovich, Barenholz
These results are significant when comparing oral versus smoking administration of CBD, where CBD was only found in the blood of mice for a period of up to 36 hours after administration.
About 50 million people worldwide suffer from epilepsy, making it one of the most common neurological disorders worldwide. GW Pharma (NASDAQ: GWPH - $3 billion market cap) is the most prominent company in the CBD pharmaceutical space and already has an approved drug (Epidyolex ® ) for Lennox-Gastaut Syndrome and Dravet Syndrome, two difficult-to-treat forms of childhood epilepsy. The drug must be taken twice a day.
CLX: CBD-LOADED EXOSOMES AGAINST COVID-19?
This news brought the company InnoCan Pharma* (WKN: A2PSPW) into the focus of investors:
InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD
InnoCan Pharma* (WKN: A2PSPW) wants to test a treatment method against Covid-19 together with Tel Aviv University. To do this, exosomes (particles that form during the formation of stem cells) are "loaded" with CBD molecules (from the cannabis plant). Exosomes have the proven ability to find damaged cells in the body and initiate a repair process. Not only does CBD have the property of being anti-inflammatory, it can also (according to the latest research) block the "gate" through which the virus enters a cell. The innovative combination is to be introduced into the lungs attacked by Covid-19 by inhalation and, in the best case, heal them.
There is ample evidence that stem cell or exosome therapy could be the key to fighting Covid-19 disease. A landmark clinical study from Christ Hospitals in Jersey City, New Jersey, USA, has been published entitled "Bone marrow mesenchymal stem cell exosomes for the treatment of severe COVID-19" (https://pubmed.ncbi.nlm).nih.gov /32380908/).
The virus is here to stay. Vaccination will bring relief, but people will still get sick with Covid-19. An effective therapy against the so-called cytokine storm caused by the virus, which can then cause lung failure (also in other infectious lung diseases), is now the top priority of the researchers. The company recently took a huge step forward in InnoCan Pharma's promising research approach to load exosomes with CBD molecules: Innocan Pharma Successfully Completes Large Scale Production of Exosomes
WITH CBD AGAINST MUSCLE PAIN + CBD BEAUTY PRODUCTS
InnoCan Pharma* (WKN: A2PSPW) recently announced that 95% of testers experience pain reduction when using the Relief & Go OTC pain relief spray (News).
Pain is the unfortunate rule in competitive sports due to the constant overstraining of joints, tendons and muscles. The patent-pending anti-pain spray tackles the problem from three sides. The combination of three active ingredients, menthol, magnesium and CBD, should make a very effective treatment possible. It should be noted that magnesium is normally only taken orally, but thanks to the patented formula it can go directly through the skin to the area of action.
InnoCan Pharma* (NASDAQ:INNO) also recently reported that its SHIR premium CBD facial serum reduced wrinkles by 90% after four weeks of treatment in a clinical study (News).
CONCLUSION:
Of course, in the near term, the main focus for investors has been the Covid-19 research. Due to its topicality, this naturally had a very broad impact. As a result, InnoCan Pharma* (NASDAQ:MMP) reached an investor audience that might have overlooked this stock at first glance. With the high-profile management directing the company's development, it should be able to put the future products and developments in perspective as well, making it highly likely that InnoCan Pharma* (NYSE:INNOCAN) could quickly develop a large following .
If you look at the price development of InnoCan over the last few months, you will see a winning share! In my opinion, this should continue in 2021.
You can find the original article HERE!
Helmut Pollinger
*Please note the following information on the conflicts of interest definitely existing at bullVestor with regard to this publication as well as our risk information and our disclaimer
Subscribe to my free newsletter
Risk Warning and Disclaimer
We expressly point out that we assume no liability for the content of external links. Every investment in securities involves risks. Political, economic or other changes can lead to significant price losses. This applies in particular to investments in (foreign) second-line stocks and in small and microcap companies. Due to the low market capitalization, investments in such securities are highly speculative and involve a high risk, up to and including the total loss of the invested capital. In addition, some of the stocks presented at bullVestor are subject to currency risks.
The background information and market assessments published by bullVestor for the German-speaking area were created in compliance with the Austrian and German capital market regulations and are therefore intended exclusively for capital market participants in the Republic of Austria and the Federal Republic of Germany. Other foreign capital market regulations were not taken into account and do not apply in any way. BullVestor's publications are for informational purposes only and expressly do not represent a financial analysis, but are promotional texts of a purely advertising nature for the companies discussed, which pay a fee for this.
No consulting contract is concluded between the reader and the authors or the publisher through the purchase of the bullVestor publications. All information and analyzes do not represent an invitation, offer or recommendation to buy or sell investment instruments or for other transactions. Every investment in shares, bonds, options or other financial products is associated with risks, some of which are considerable.
The editors and authors of the bullVestor publications are not professional investment advisors. It is therefore essential that you always seek advice from a qualified specialist (e.g. your house bank or a qualified advisor you trust) when making your investment decisions. All information and data published by bullVestor comes from sources that we believe to be reliable and trustworthy at the time of writing. However, no guarantee can be given with regard to the correctness and completeness of this information and data.
The same applies to the evaluations and statements contained in bullVestor's analyzes and market assessments. These were created with due care. Any responsibility or liability for the correctness and completeness of the information contained in this publication is excluded. All statements of opinion made reflect the current assessment of the authors, which can change at any time without prior notice. There is expressly no guarantee or liability that the price or profit developments forecast in the bullVestor publications will occur.
Conflicts of Interest Disclosures
The publisher and responsible authors hereby declare that the following conflicts of interest exist with regard to the company discussed in this publication at the time of publication:
Imprint:
bullVestor Medien GmbHGutenhofen 44300 St. Valentin AustriaTel: +43 7435 54077-0 Company registration number: FN275279yManaging director and 100% owner: Helmut PollingerPlace of jurisdiction: St. Pöltenkontakt[at]bullvestor.at- advertisement -
Values included: CA45783P1027
